TOBI tobramycin

Drug Class

Aminoglycoside antibacterial

Mechanism

Binds irreversibly to the 30S ribosomal subunit of Pseudomonas aeruginosa, inhibiting bacterial protein synthesis and causing cell membrane disruption and cell death.

Approved Indication

Management of cystic fibrosis patients with Pseudomonas aeruginosa.

What This Means For Patients

TOBI is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (1997) — Sources

Pivotal Clinical Evidence

• Ramsey et al., 1999 — Ramsey et al., N Engl J Med 1999 — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050755s017lbl.pdf